USFDA inspection of Liva Pharmaceuticals concludes with 5 observations
Cadila Healthcare announced that USFDA inspected the injectables manufacturing facility of Liva Pharmaceuticals (Liva) which is located at Vadodara, from 20 August 2018 to 28 August 2018. Liva is a 100% subsidiary of Cadila Healthcare.This was a product specific Pre Approval Inspection. The inspection concluded with 5 observations. Liva will respond to the USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
